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CDS

:   coding DNA sequence

NGS

:   next‐generation sequencing

SNP(s)

:   single‐nucleotide polymorphism(s)

WGS

:   whole genome sequencing

Prediction of red blood cell (RBC) and platelet (PLT) antigens using DNA assays has the potential to augment or replace traditional serologic antigen typing in many situations. DNA‐based typing methods are more easily automated, amenable to multiplexing, and do not require expensive and sometimes difficult to obtain serologic immunoglobulin reagents. As such, DNA‐based approaches could allow for more extensive characterization of patient and donor phenotypes and enable enhanced blood product selection and identification of donors with rare phenotypes.

There are 346 serologically distinct RBC blood group antigen phenotypes recognized by the International Society of Blood Transfusion (ISBT).[1](#trf13416-bib-0001){ref-type="ref"} For most RBC antigens there is a known correlation between the antigen phenotype and one or more molecular changes defined by more than 1100 alleles across 45 genes.[2](#trf13416-bib-0002){ref-type="ref"}, [3](#trf13416-bib-0003){ref-type="ref"}, [4](#trf13416-bib-0004){ref-type="ref"}, [5](#trf13416-bib-0005){ref-type="ref"}, [6](#trf13416-bib-0006){ref-type="ref"}, [7](#trf13416-bib-0007){ref-type="ref"}, [8](#trf13416-bib-0008){ref-type="ref"}, [9](#trf13416-bib-0009){ref-type="ref"} There are 33 serologically distinct human PLT antigen (HPA) phenotypes recognized by the Platelet Nomenclature Committee.[10](#trf13416-bib-0010){ref-type="ref"} For all 33 PLT antigens, the molecular basis is known and can be characterized by 33 alleles within six genes.[10](#trf13416-bib-0010){ref-type="ref"}, [11](#trf13416-bib-0011){ref-type="ref"}, [12](#trf13416-bib-0012){ref-type="ref"} Resources that catalog RBC antigen allele variants include the ISBT website,[2](#trf13416-bib-0002){ref-type="ref"} the Blood Group Antigen FactsBook,[3](#trf13416-bib-0003){ref-type="ref"} the BGMUT website,[13](#trf13416-bib-0013){ref-type="ref"} and the *RHD* RhesusBase.[14](#trf13416-bib-0014){ref-type="ref"} Alleles encoding PLT antigens are available from the Immuno Polymorphism Database‐HPA website.[10](#trf13416-bib-0010){ref-type="ref"}, [11](#trf13416-bib-0011){ref-type="ref"}, [12](#trf13416-bib-0012){ref-type="ref"} These resources provide a means to validate and design single‐nucleotide polymorphism (SNP) assays to predict phenotypes. However, current SNP‐based molecular typing assays have limitations[15](#trf13416-bib-0015){ref-type="ref"}, [16](#trf13416-bib-0016){ref-type="ref"} including: 1) need for specialized testing instruments, reagents, and workflows; 2) do not include all of the known blood group genes; 3) target selective gene regions without evaluating all potentially contributory genetic changes; and 4) more complex antigens require the integration of multiple assays.[16](#trf13416-bib-0016){ref-type="ref"}

The RH (e.g., D, C/c, E/e) and MNS (e.g., M/N, S/s) blood group system antigens are challenging to predict given the large number of complex alleles, genetic variation, and gene rearrangements between *RHD*/*RHCE* and *GYPA*/*GYPB*/*GYPE*. Most of the other RBC protein antigens (e.g., K/k, Fy^a/b^) are the result of single well‐characterized inherited missense variants.[3](#trf13416-bib-0003){ref-type="ref"}, [4](#trf13416-bib-0004){ref-type="ref"} However, additional molecular changes can cause antigen expression to be weak or silenced (null) due to alternative splicing, premature stop codons, hybrid genes, promoter silencing, and at the protein level, altered membrane insertion or changes to interacting proteins or modifying genes. High‐resolution predictive accuracy would require large regions of sequence coverage to identify all potentially relevant changes. Although commercial SNP assays evaluate common polymorphisms to predict protein‐based antigens,[15](#trf13416-bib-0015){ref-type="ref"}, [17](#trf13416-bib-0017){ref-type="ref"} they do not include all clinically significant changes.

The RBC carbohydrate antigens (e.g., ABO, Le^a/b^, P1, P^k^) are synthesized by enzymes.[3](#trf13416-bib-0003){ref-type="ref"} DNA‐based determination of carbohydrate antigen expression is not widespread because accurate prediction requires gene sequencing to properly predict the enzymatic and sugar specificity across several genes (e.g., ABO antigen prediction requires evaluation of *ABO* along with *FUT1* [3](#trf13416-bib-0003){ref-type="ref"}, [19](#trf13416-bib-0019){ref-type="ref"} and *FUT2* [21](#trf13416-bib-0021){ref-type="ref"}, [22](#trf13416-bib-0022){ref-type="ref"}). In addition, alleles associated with carbohydrate antigens are complex, often contain multiple nucleotide changes, and are numerous (e.g., \>300 *ABO* alleles reported[13](#trf13416-bib-0013){ref-type="ref"}), with many different null alleles. The clinical significance of missing one inactivating mutation for ABO is an unacceptable risk for transfusion and, therefore, the limited sequence coverage of SNP targeted typing is currently inadequate.

PLT antigens are mainly associated with single missense variants.[23](#trf13416-bib-0023){ref-type="ref"} Although molecular assays exist to predict PLT antigens,[24](#trf13416-bib-0024){ref-type="ref"} matching for patients, with the possible exception of HPA‐1a, is underutilized in clinical practice at the present time given the cost and lack of antigen typed donors.

Next‐generation sequencing (NGS) would overcome many of the limitations associated with SNP‐based assays. NGS‐based molecular prediction has been successfully applied to human leukocyte antigens[25](#trf13416-bib-0025){ref-type="ref"}, [26](#trf13416-bib-0026){ref-type="ref"}, [27](#trf13416-bib-0027){ref-type="ref"}, [28](#trf13416-bib-0028){ref-type="ref"}, [29](#trf13416-bib-0029){ref-type="ref"}, [30](#trf13416-bib-0030){ref-type="ref"} and human neutrophil antigens.[31](#trf13416-bib-0031){ref-type="ref"} However, there are no published reports of NGS‐based PLT antigen prediction and only three reports of targeted NGS‐based RBC antigen prediction: 1) *RHD* in 26 samples with weak D antigens,[32](#trf13416-bib-0032){ref-type="ref"} 2) K/k allelic polymorphism (c.578) using cell‐free fetal DNA in three pregnant females,[33](#trf13416-bib-0033){ref-type="ref"} and 3) 18 genes that control 15 blood group systems in four individuals.[34](#trf13416-bib-0034){ref-type="ref"} Recently, an algorithm was published[35](#trf13416-bib-0035){ref-type="ref"} that used the BGMUT database[13](#trf13416-bib-0013){ref-type="ref"} to predict RBC antigens for ABO and D typed individuals from the personal genome.[36](#trf13416-bib-0036){ref-type="ref"}, [37](#trf13416-bib-0037){ref-type="ref"}

With the emergence of genomic approaches and personalized medicine, NGS‐based whole genome sequencing (WGS) data could be used to evaluate genes encoding RBC and PLT antigens to predict the presence of antigens with a known molecular basis. There are no reports describing comprehensive WGS‐based RBC or PLT antigen prediction. One of the challenges for this approach is that the allele reference sources list the nucleotide changes according to coding DNA sequence (CDS) positions based on cDNA sequences. It is not readily possible to predict RBC and PLT antigens from WGS data, since the data use genomic coordinates linked to the human reference genome. In this article we describe an approach for the prediction of RBC and PLT antigens from WGS data and demonstrate the feasibility of the approach.

MATERIALS AND METHODS {#trf13416-sec-0006}
=====================

Conversion of conventional cDNA positions to genomic coordinates {#trf13416-sec-0007}
----------------------------------------------------------------

Conventional cDNA reference sequence CDS positions were converted to genomic coordinates: 1) reference cDNA and protein sequences were downloaded from GenBank; 2) human reference genome UCSC genomic transcripts, corresponding to the splicing pattern of the conventional cDNA sequence, were downloaded in a format identifying the exons and introns and the genomic start and end positions (exons, uppercase; introns, lowercase); 3) the cDNA reference sequence and the human reference genome sequences were aligned using Clustal Omega v1.1.1;[38](#trf13416-bib-0038){ref-type="ref"} 4) the start and termination codon genomic positions were manually determined in the Integrated Genomic Viewer Version 2.3.26;[39](#trf13416-bib-0039){ref-type="ref"} and 5) the CDS start position and alignments were then used as a reference to convert between cDNA, gene, and genomic coordinate positions.

Predicting antigens from the human reference genome {#trf13416-sec-0008}
---------------------------------------------------

RBC and PLT antigens encoded by each cDNA reference sequence are well established.[2](#trf13416-bib-0002){ref-type="ref"}, [3](#trf13416-bib-0003){ref-type="ref"}, [10](#trf13416-bib-0010){ref-type="ref"} The conventional cDNA reference and human reference genome alignments were used to determine the CDS and amino acid positions that differed. The known alleles[2](#trf13416-bib-0002){ref-type="ref"}, [3](#trf13416-bib-0003){ref-type="ref"}, [4](#trf13416-bib-0004){ref-type="ref"}, [10](#trf13416-bib-0010){ref-type="ref"}, [12](#trf13416-bib-0012){ref-type="ref"}, [23](#trf13416-bib-0023){ref-type="ref"} were used to manually determine if any difference altered the presence or absence of a RBC and PLT antigen, which allowed for the prediction of the RBC and PLT antigens encoded by the human reference genome.

WGS‐based antigen prediction {#trf13416-sec-0009}
----------------------------

With approval from the Partners HealthCare Human Research Committee, a sample for RBC phenotyping and genomic DNA isolation was collected from a patient participating in the MedSeq Project.[40](#trf13416-bib-0040){ref-type="ref"} Whole genomic sequencing was performed by the CLIA‐certified, CAP‐accredited Illumina Clinical Services Laboratory (San Diego, CA) using paired‐end 100‐bp reads on the Illumina HiSeq platform and sequenced to at least 30× mean coverage.[41](#trf13416-bib-0041){ref-type="ref"} The genomic data from the MedSeq project has being submitted to the dbGaP website. The genome used in this article is from dbGaP subject ID 1270611. Sequence read data were aligned to the human reference sequence (GRCh37/hg19) using Burrows‐Wheeler Aligner 0.6.1‐r104.[42](#trf13416-bib-0042){ref-type="ref"} Variant calls for 45 RBC and six HPA genes (300 bases upstream of start codon, exons, and 10 bases into each intron) were made using the Genomic Analysis Tool Kit Version 2.3‐9‐gdcdccbb and saved as a variant calling format (.vcf) file showing differences between the WGS data and the reference genome.[43](#trf13416-bib-0043){ref-type="ref"} Sequencing coverage was extracted from the alignment file using BEDTools v2.17.0.[44](#trf13416-bib-0044){ref-type="ref"} The Integrative Genomics Viewer[39](#trf13416-bib-0039){ref-type="ref"} was used to verify coverage and sequence identity for positions in the .vcf file.

The genomic coordinates from the .vcf file were converted into CDS positions relative to the conventional cDNA sequences. Each variant was then compared to published allele tables.[2](#trf13416-bib-0002){ref-type="ref"}, [3](#trf13416-bib-0003){ref-type="ref"}, [4](#trf13416-bib-0004){ref-type="ref"}, [10](#trf13416-bib-0010){ref-type="ref"}, [12](#trf13416-bib-0012){ref-type="ref"}, [23](#trf13416-bib-0023){ref-type="ref"} For alleles with nucleotide changes in the 3′, 5′, and intronic regions, the genomic coordinates were manually determined and evaluated in the NGS alignment file for the presence or absence of the antigen from published allele tables.[2](#trf13416-bib-0002){ref-type="ref"}, [3](#trf13416-bib-0003){ref-type="ref"}, [4](#trf13416-bib-0004){ref-type="ref"}, [10](#trf13416-bib-0010){ref-type="ref"}, [12](#trf13416-bib-0012){ref-type="ref"}, [23](#trf13416-bib-0023){ref-type="ref"} To predict antigens with positions not in the .vcf file, the sequence coverage was analyzed for adequacy and if adequate the human reference genome prediction was used.

RBC serology {#trf13416-sec-0010}
------------

RBC serologic antigen typing by tube method was performed according to standard blood banking practices in the Brigham and Women\'s Hospital Blood Bank. Commercially available serologic typing reagents were used to type for the ABO, D, c, C, e, E, K, k, Fy^a^, Fy^b^, Jk^a^, Jk^b^, M, N, S, and s antigens.

RESULTS {#trf13416-sec-0011}
=======

Conversion of cDNA positions to genomic coordinates {#trf13416-sec-0012}
---------------------------------------------------

RBC and PLT antigen polymorphisms have historically been defined using CDS positions referenced to published cDNA sequences with the A of the start codon (ATG) as Position 1. To predict antigens from NGS data, a manual workflow was created to map the CDS nucleotide changes to the respective genomic coordinates using alignments between the cDNA reference sequence and the GRCh37/hg19 human reference genome sequence for the cDNA, CDS, and protein sequences. Figure [1](#trf13416-fig-0001){ref-type="fig"} and Table [1](#trf13416-tbl-0001){ref-type="table-wrap"} illustrate the process for the Duffy system. The Fy^a^/Fy^b^ antigens, c.125G/A, map to chr1:159,175,354G/A, and genomic coordinates were also determined for other reported FY alleles.

![Approach for mapping conventional cDNA reference sequence positions to genomic coordinates. (A) Process developed to convert conventional CDS positions to genomic coordinates with FY as an example. (B) CDS positions referenced to cDNA sequence. (C and D) Genome transcript and genomic coordinates according to the human reference genome. (E) UCSC genomic sequence in which each exon and intron is annotated as separate sequence entry preceded by the genomic coordinates. The sequence regions are colored: 3′ and 5′ (gray), CDS (green uppercase), and intron (blue lowercase). (F) FY gene conversion between genomic coordinates and cDNA reference sequence.](TRF-56-743-g001){#trf13416-fig-0001}

###### 

FY alleles, cDNA and genomic coordinates, bases(s) found, WGS coverage, and result

  Allele            CDS         Gene          Genome                              Base(s) found      Coverage   Result
  ----------------- ----------- ------------- ----------------------------------- ------------------ ---------- ----------
  *FY\*01N.01*      c.−67       g.881         chr1:159,174,683                    T                  28×        Absent
  *FY\*01/02*       c.125       g.1552        chr1:159,175,354                    G/A                15/15×     Fy(a+b+)
  *FY\*02M.02*      c.145       g.1572        chr1:159,175,374                    G                  24×        Absent
  *FY\*02M.01/02*   c.265       g.1692        chr1:159,175,494                    C                  27×        Absent
  *FY\*01N.02*      c.281_295   g.1708_1722   chr1:159,175,510_chr1:159,175,524   CTGGCT GGCCTGTCC   31‐36×     Absent
  *FY\*01N.04*      c.287       g.1714        chr1:159,175,516                    G                  34×        Absent
  *FY\*02M.01/02*   c.298       g.1725        chr1:159,175,527                    G                  32×        Absent
  *FY\*01N.05*      c.327       g.1754        chr1:159,175,556                    C                  37×        Absent
  *FY\*02N.02*      c.407       g.1834        chr1:159,175,636                    G                  27×        Absent
  *FY\*01N.03*      c.408       g.1835        chr1:159,175,637                    G                  28×        Absent

Differences between conventional cDNA and human reference genome {#trf13416-sec-0013}
----------------------------------------------------------------

From the conversion and alignment process, differences were observed between conventional cDNA and the human reference genome. Minor differences included: 1) silent variants that do not encode amino acid changes, 2) different antigen allele, and 3) potentially nonrelevant missense changes. Table [2](#trf13416-tbl-0002){ref-type="table-wrap"} summarizes the blood group, gene, nucleotide, and amino acid differences; location of change; or predicted impact on antigen expression. Major differences that would challenge interpretation were encountered in the following genes: *ABO*, *A4GALT*, *RHD*, *RHCE*, *FUT3*, *ACKRI* (previously *DARC*), *ACHE*, *FUT2*, *CR1*, *GCNT2*, and *RHAG*, summarized in Table [2](#trf13416-tbl-0002){ref-type="table-wrap"}.

###### 

Differences encountered when aligning the conventional cDNA with the human reference genome (shown as conventional reference \> reference genome)

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Symbol   Gene       CDS nucleotide (genomic coordinate) \[amino acid\]                                                                                                                                                       Differences
  -------- ---------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ABO      *ABO*      c.261delG (no genomic coordinate)                                                                                                                                                                        Genome: inactive enzyme\
                                                                                                                                                                                                                               Exons 1‐5 correspond to *ABO.O.01.02* Exons 6 and 7 correspond to *ABO\*O.01.01*

  MNS      *GYPA*     c.38(chr4:145,041,741)C\>A \[p.Ala13Glu\]; c.59(chr4:145,041,720)C\>T \[p.Ser20Lue\], c.71(chr4:145,041,708)G\>A, c.72(chr4:145,041,707)T\>G \[p.Gly24Glu\]; c.93(chr4:145,041,686)C\>T \[p.Thr31Thr\]   Probable nonrelevant missense change in cleaved N‐term;\
                                                                                                                                                                                                                               Antigenic difference: M+N−\>M−N+;\
                                                                                                                                                                                                                               Silent change

  MNS      *GYPB*     c.251(chr4:144,918,712)C\>G \[p.Thr84Ser\]                                                                                                                                                               Presumed non‐relevant missense change c.251G is part of the S−s−U+w \[GYPB.NY\] allele which has additional changes c.208G\>T and c.230C\>T not present in the reference genome

  P1PK     *A4GALT*                                                                                                                                                                                                            Two different cDNA reference sequences

  RH       *RHD*      c.1136(chr1:25,643,553)C\>T \[p.Thr379Met\]                                                                                                                                                              Genome: common African black allele

  RH       *RHCE*     c.48(chr1:25,747,230)G\>C \[p.Trp16Cys\]                                                                                                                                                                 Genome: common African black allele

  LU       *BCAM*\    c.1615(chr19:45,322,744)G\>A \[p.Ala539Thr\]                                                                                                                                                             Antigenic difference: Au(a−b+) \> Au(a+b−)
           (*LU*)                                                                                                                                                                                                              

  LE       *FUT3*     c.202(chr19:5,844,649)T\>C \[p.Trp68Arg\], c.314(chr19:5,844,537)C\>T \[p.Thr105tMet\]                                                                                                                   Genome: inactive enzyme associated with a Le(a−b−) phenotype

  FY       *ACKR1*\                                                                                                                                                                                                            Conventional: reference is alternative splice form with different numbering than the alleles
           (*DARC*)                                                                                                                                                                                                            

  DI       *SLC4A1*   c.357(chr17:42,337,900)T\>C \[p.Val119Val\]                                                                                                                                                              Silent change

  YT       *ACHE*                                                                                                                                                                                                              Conventional reference is alternative splice form with different numbering and splice form was not deposited into GenBank

  DO       *ART4*     c.378(chr12:14,993,854)C\>T \[p.Tyr126Tyr\], c.624(chr12:14,993,608)T\>C \[p.Leu208Leu\]; c.793(chr12:14,993,439)A\>G \[p.Asn265Asp\]                                                                    Silent changes;\
                                                                                                                                                                                                                               Antigenic difference: Do(a+b−) \> Do(a−b+)

  H        *FUT2*                                                                                                                                                                                                              Conventional reference is numbered to alternative splice form rather than the deposited long isoform

  KN       *CR1*      c.4828(chr1:207,782,916)T\>A \[p.Ser1610Thr\]                                                                                                                                                            Genome: rare Sl3-- phenotype

  IN       *CD44*     c.326(chr11:35,201,913)A\>C \[p.Tyr109Ser\]                                                                                                                                                              Found in association with rare In(a+b−) phenotype but with additional changes c.137G\>C p.Arg46Pro and c.716G\>A p.Gly239Glu. It is unclear if c.326A\>C alone can lead to antigenic change.

  OK       *BSG*      c.537(chr19:581,407)T\>C \[p.Asp179Asp\]                                                                                                                                                                 Silent change

  RAPH     *CD151*    c.579(chr11:837,582)A\>G \[p.Gly193Gly\]                                                                                                                                                                 Silent change

  I        *GCNT2*    c.816(chr6:10,587,038)G\>C \[p.Glu272Asp\]                                                                                                                                                               Genome: uncommon allele with unclear phenotype

  GIL      *AQP3*     c.61(chr9:33,447,468)T\>C \[p.Leu21Leu\], c.105(chr9:33,447,424)C\>G \[p.Leu35Leu\], c.390(chr9:33,442,952)T\>C \[p.Phe130Phe\], c.543(chr9:33,442,466)T\>C \[p.Pro181Pro\]                              Silent changes

  RHAG     *RHAG*     c.724(chr6:49,582,483)G\>A \[p.Asn242Asp\]                                                                                                                                                               Conventional reference sequence sequencing error
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

### ABO {#trf13416-sec-0014}

The *ABO* gene determines the transferase enzymes responsible for the carbohydrate antigens, A and B. Any mutation that results in absence of transferase activity results in Group O. The conventional cDNA reference is an *A* allele. By analyzing the *ABO* gene region in the human reference genome it was found to represent sequence regions from two separate human reference genome sequencing contigs representing different haplotype alleles: 1) The AL158826.23 contig, which contains Exons 1 to 5 corresponds to the *ABO.O.01.02* allele, and 2) the AL732364.9 contig, which contains Exons 6 to 7 matches the *ABO\*O.01.01* allele.[3](#trf13416-bib-0003){ref-type="ref"} Therefore, the reference sequence contains a deletion characteristic of *O^1^* alleles (c.261delG) and when analyzing NGS data *A* and *B* allele sequences would appear to have an insertion (chr1:136132908_136132909insG) and *O^1^* alleles would not have the characteristic deletion.

### A4GALT (P1PK) {#trf13416-sec-0015}

The *A4GALT* gene encodes a lactosylceramide 4‐α‐galactosyltransferase enzyme responsible for the carbohydrate P1PK system antigens: P1 and P^k^. All of the known P1PK null alleles are referenced using the splice form I reference sequence (GU902278‐GU902281), but all of the nucleotides associated with P1+ and P1− expression are located in a skipped Exon 2a, which is only found in the alternative spliced form IV of *A4GALT* (AJ245581).[45](#trf13416-bib-0045){ref-type="ref"} Therefore, mapping required use of both conventional reference sequences to obtain the corresponding genomic coordinates.

### RH {#trf13416-sec-0016}

Relative to the conventional reference sequence for *RHD* (L08429) the human reference genome is c.1136C\>T (chr1:25,643,553C\>T) p.Thr379Met, which corresponds to the family of DAU alleles,[46](#trf13416-bib-0046){ref-type="ref"} specifically *RHD\*DAU0,* which is primarily found in African Americans.[47](#trf13416-bib-0047){ref-type="ref"} The conventional reference sequence (DQ322275) for *RHCE\*ce* (*RHCE\*01)* encodes a c+e+ phenotype.[46](#trf13416-bib-0046){ref-type="ref"}, [47](#trf13416-bib-0047){ref-type="ref"}, [48](#trf13416-bib-0048){ref-type="ref"} The human reference genome *RHCE* sequence is c.48G\>C, chr1:25,747,230G\>C (p.Trp16Cys),[49](#trf13416-bib-0049){ref-type="ref"} which corresponds to *RHCE\*ce(48C)* (*RHCE\*01.01),* again, an allele more often found in African Americans.

### ACKRI previously DARC (FY) {#trf13416-sec-0017}

The gene that encodes the Duffy antigens, Fy^a^ and Fy^b^, has a minor 338 amino acid product (Variant 1, U01839) and a major 336‐amino‐acid product (Variant 2, NM_002036.3).[3](#trf13416-bib-0003){ref-type="ref"}, [50](#trf13416-bib-0050){ref-type="ref"}, [51](#trf13416-bib-0051){ref-type="ref"} The nucleotide position responsible for the Fy^a^/Fy^b^ phenotype is c.131G/A (p.Gly44Asp) in Variant 1 and c.125G/A (p.Gly42Asp) in Variant 2.[52](#trf13416-bib-0052){ref-type="ref"} Some allele sources list the reference sequence as U01839,[2](#trf13416-bib-0002){ref-type="ref"}, [3](#trf13416-bib-0003){ref-type="ref"} but many of the null allele nucleotide positions did not correlate with the U01839 sequence. The original report[52](#trf13416-bib-0052){ref-type="ref"} used Variant 1 (which they did not deposit at the time of publication, but corresponds to NM_002036.3). The two sequences differ in length by six nucleotides, and both sequences have a GAC (Gly) codon six nucleotides upstream of the actual Fy^a^ GAC (Gly) codon, making the disparity in reference sequence difficult to detect.

### FUT3 {#trf13416-sec-0018}

Relative to the conventional reference sequence (X53578), the human reference genome sequence is a reported inactive form of the enzyme with nucleotide changes c.202T\>C (chr19:5,844,649T\>C) p.Trp68Arg and c.314C\>T (chr19:5,844,537C\>T) p.Thr105tMet corresponding to a Le(a−b−) phenotype.[53](#trf13416-bib-0053){ref-type="ref"}

### ACHE (YT) {#trf13416-sec-0019}

*ACHE* has several alternative splicing variants including: 1) the conventional cDNA reference sequence (Variant 1, M55040, 614 amino acids) and 2) a cDNA sequence that is primarily expressed in erythroid tissue (Variant 2, NM_015831.2, 617 amino acids).[54](#trf13416-bib-0054){ref-type="ref"}, [55](#trf13416-bib-0055){ref-type="ref"} Variant 1 and Variant 2 only differ in the C‐terminal region and the nucleotide numbering of the only known antigens (Yt^a^ and Yt^b^) are not affected by this difference. Published allele source lists the conventional cDNA reference sequence (Variant 1), but shows the amino acid sequence for Variant 2.[3](#trf13416-bib-0003){ref-type="ref"}

### FUT2 {#trf13416-sec-0020}

The *FUT2* gene product has two isoforms: a 332‐amino‐acid short isoform and a 334‐amino‐acid long isoform (extra 11 amino acid N‐term). The original *FUT2* paper found both isoforms, but although secretor mutations were referenced to the short isoform, only the long isoform was submitted (U17894).[56](#trf13416-bib-0056){ref-type="ref"} Subsequent alleles have continued to be referenced to the short isoform, but incorrectly list the long isoform as reference.[2](#trf13416-bib-0002){ref-type="ref"}, [3](#trf13416-bib-0003){ref-type="ref"} We took the long isoform (UCSC transcript: uc002pke.4) and removed the first 33 nucleotide (11 amino acids) so that the allele positions would correlate with those published.

### CR1 (KN) {#trf13416-sec-0021}

Relative to the conventional reference sequence (Y00816), the human reference genome is c.4828T\>A (chr1:207,782,916T\>A) p.Ser1610Thr, which corresponds to the allele encoding lack of the high frequency Knops antigen (Sl3) and a Sl3− (Sl:1,−2,−3) phenotype.[57](#trf13416-bib-0057){ref-type="ref"} The Exome Variant Server[58](#trf13416-bib-0058){ref-type="ref"} was used to determine the allele frequency for c.4828T\>A, which is 2.5% (207/8041) European Americans and 0.4% (16/3818) African Americans.

### GCNT2 (I) {#trf13416-sec-0022}

Relative to the conventional reference sequence for *GCNT2* (AF458026), the human reference genome is c.816G\>C (chr6:10,587,038G\>C) p.Glu272Asp, which according to one source[2](#trf13416-bib-0002){ref-type="ref"} is the null allele *GCNT2\*N.03* that encodes for an I− (i adult) phenotype associated with cataracts. However, although c.816G\>C was found in an individual with an I− (i adult) phenotype, it was present with another change c.1006G\>A, Gly336Arg (*GCNT2\*N.04*).[59](#trf13416-bib-0059){ref-type="ref"} BGMUT indicates c.816G\>C has been found in both adult I+ and I− (i adult) individuals. The Exome Variant Server[58](#trf13416-bib-0058){ref-type="ref"} was used to determine the allele frequency for c.816G\>C (dbSNP rs539351) as 0.1% (11/8589) European Americans and 0.05% (2/4404) African Americans.

### RHAG {#trf13416-sec-0023}

Relative to the conventional reference sequence for *RHAG* (X64594) the human reference genome is c.724G\>A (chr6:49,582,483G\>A) p.Asp242Asn. However, aside from the original *RHAG* report (X64594),[60](#trf13416-bib-0060){ref-type="ref"} all subsequent sequences are c.724A p.Asn242 (AF031549, AF179682, AF179684, AF179685, AF187847, AF178841), and dbSNP indicates that c.742A p.Asn242 (rs1058063) has an allele frequency of 100% and is found in 590 of 590 tested chromosomes from a mix of Europeans, Asians, and Africans. Therefore, the c.724G in X64594 was likely a sequencing error with c.724A being the correct nucleotide.

Comprehensive whole genome antigen prediction {#trf13416-sec-0024}
---------------------------------------------

WGS data from a 47‐year‐old female of European ethnicity in generally good health were first analyzed to determine the sequencing coverage of the genes encoding RBC and PLT antigens. For genes encoding the RBC antigens there was an average coverage of 34× over 1,091,334 bp (Fig. [2](#trf13416-fig-0002){ref-type="fig"}, Fig. S1 \[available as supporting information in the online version of this paper\], Tables [1](#trf13416-tbl-0001){ref-type="table-wrap"} and [3](#trf13416-tbl-0003){ref-type="table-wrap"}). For genes encoding PLT antigens, there was an average coverage of 38× over 323,222 bp (Fig. [2](#trf13416-fig-0002){ref-type="fig"}, Fig. 1S, Table [4](#trf13416-tbl-0004){ref-type="table-wrap"}). There were some regions with missing sequence coverage and/or poor sequencing quality in the following RBC genes: *RHD* (Exon 8), *C4B*, *C4A*, and *CR1* (Fig. [2](#trf13416-fig-0002){ref-type="fig"}, Fig. 1S). However, all of the RBC and PLT genes had adequate sequencing coverage (Fig. 1S) and quality to allow for prediction of phenotypes from the known allele nucleotide positions. The low coverage for *RHD* Exon 8 is likely due to the human reference genome Exon 8 containing a mismatched *RHD\*DAU0* allele change. In addition, without the presence of the *RHD\*DAU0* allele, Exon 8 is identical in both *RHD* and *RHCE*. Therefore, *RHD* Exon 8 sequences either misaligned to *RHD* and/or did not align at all.

![**WGS‐based RBC and PLT gene sequencing. Circos plot** [61](#trf13416-bib-0061){ref-type="ref"} **of the WGS data that has been filtered to only show the RBC and PLT genes with a circular plot of the sequence coverage (100‐bp bins).**](TRF-56-743-g002){#trf13416-fig-0002}

###### 

Comprehensive RBC antigen prediction from a patient\'s whole genome[a](#trf13416-note-0002){ref-type="fn"}

  System      Gene                      Average coverage                                                                                                           Phenotypes
  ----------- ------------------------- -------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  001 ABO     *FUT1, ABO*               27×, 31×                                                                                                                   A1
  002 MNS     *GYPA*                    41×                                                                                                                        M+N+, Vr−, Mt(a−), Ri(a−), Ny(a−), Or−, ERIK−, Os(a−), ENEP+, ENEH+, ENAV+, ENEV+, MNTD−
  *GYPB*      45×                       S+s+, U+, En(a+), He−, Mi(a−), Mur−, Mv−, s(D−), Mit−, Dantu−                                                              
  003 P1PK    *A4GALT*                  29×                                                                                                                        P1+/P1−, pk+, NOR−
  004 RH      RHD                       34×                                                                                                                        D+, Tar−
  *RHCE*      33×                       C−c+E+e−, C^W^−, C^X^−, E^W^−, V−, VS−, Rh26+LOCR−, Be(a−), DAK−, Go(a−), Rh32−, Crawford−CELO+, JAL−CEST+, STEM−, JAHK−   
  005 LU      *BCAM(LU), KLF1, GATA1*   24×, 21×, 25×                                                                                                              Lu(a−b+), LURC+, Lu4+, Lu5+, Lu6+, Lu7+, Lu8+, Lu13+, Lu16+, Lu17+, Au(a+b−), Lu20+, Lu21+
  006 KEL     *KEL*                     33×                                                                                                                        K−k+, Kp(a−b+c−), Js(a−b+), Ul(a−), K11+, K12+, K13+, K14+, K18+, K19+, K22+, K23−, VLAN−VONG−, TOU+, RAZ+, KALT+, KTIM+, KYO−, KUCI+, KANT+, KASH+, KELP+, KETI+, KHUL+
  007 LE      *FUT2,3*                  28×, 28×, 27×, 23×                                                                                                         Le(a+b−)
  008 FY      *ACKR1(DARC)*             28×                                                                                                                        Fy(a+b+)
  009 JK      *SLC14A1*                 37×                                                                                                                        Jk(a+b+)
  010 DI      *SLC4A1*                  26×                                                                                                                        Di(a−b+), Wr(a−b+), Wd(a−), Rb(a−), WARR−, ELO−, Bp(a−), Mo(a−), Hg(a−), Vg(a−), Sw(a−), BOW−, NFLD−, Jn(a−), KREP−, Tr(a−), Fr(a−), SW1−, Wu−DISK+
  011 YT      *ACHE*                    23×                                                                                                                        Yt(a+b−)
  013 SC      *ERMAP*                   37×                                                                                                                        Sc1+Sc2−, Rd−, STAR+, SCER+, SCAN+
  014 DO      *ART4*                    40×                                                                                                                        Do(a+b+), Jo(a+), DOYA+, Hy+, DOMR+, DOLG+
  015 CO      *AQP1*                    27×                                                                                                                        Co(a+b−), Co4+
  016 LW      *ICAM4*                   23×                                                                                                                        LW(a+b−)
  017 CH/RG   *C4B*                     25×                                                                                                                        Ch1+, Ch2+, Ch3+, Ch4+, Ch5+, Ch6+, Rg1−, Rg2−
  017 CH/RG   *C4A*                     25×                                                                                                                        Ch1−, Ch2−, Ch3−, Ch4−, Ch5−, Ch6−, Rg1+, Rg2+
  018 H       *FUT1,2,SLC35C1*          27×, 28×, 29×                                                                                                              H+
  019 XK      *XK*                      39×                                                                                                                        Kx+
  020 GE      *CYPC*                    32×                                                                                                                        Ge2+, Ge3+, Ge4+, Es(a+), Wb−, An(a−), Dh(a−), GEIS−, GELP+, GEAT+, GETI+
  021 CROM    *CD55*                    43×                                                                                                                        Cr(a+), Tc(a+b−c−), Dr(a+), Es(a+), WES(a−b+), UMC+, GUTI+, SERF+, ZENA+, CROV+, CRAM+, CROZ+
  022 KN      *CR1*                     35×                                                                                                                        Kn(a+b−), McC(a+b−), Sla+Vil−, Yk(a+), Sl3+, KCAM+/KCAM−
  023 IN      *CD44*                    39×                                                                                                                        In(a−b+), INFI+, INJA+
  024 OK      *BSG*                     22×                                                                                                                        Ok(a+), OKGV+, OKVM+
  025 RAPH    *CD151*                   22×                                                                                                                        MER2+
  026 JMH     *SEMA7A*                  27×                                                                                                                        JMHK+, JMHL+, JMHG+, JMHM+, JMHQ+
  027 I       *GCNT2*                   37×                                                                                                                        I+
  028 GLOB    *B3GALNT1*                40×                                                                                                                        P+
  029 GIL     *AQP3*                    27×                                                                                                                        GIL+
  030 RHAG    *RHAG*                    39×                                                                                                                        Duclos+, Ol(a−), DSLK+, RHAG4−
  031 FORS    *GBGT1*                   27×                                                                                                                        FORS+
  032 JR      *ABCG2*                   37×                                                                                                                        Jra+
  033 LAN     *ABCB6*                   29×                                                                                                                        Lan+
  034 VEL     *SMIM1*                   22×                                                                                                                        Vel+
  035 CD59    *CD59*                    36×                                                                                                                        CD59.1+
  036 AT      *SLC29A1*                 28×                                                                                                                        At(a+)

Serologic RBC confirmation = A+, B−, D+, C−, c+, E+, e−, K−, k+, Fy(a+b+), Jk(a+b+), M+, N+, S+, s+.

*FUT1* = active; *FUT2* = inactive; *FUT3* = active; *SLC35C1* = active; *ABO* = active A1; *B3GALNT1* = active; *GCNT2* = active; *GBGT1* = inactive; *KLF1* = active; *GATA1* = active.

###### 

Comprehensive PLT antigen prediction from a patient\'s whole genome

  Gene       Average coverage   Predicted HPA phenotypes
  ---------- ------------------ ---------------------------------------------------------------------------------------------------
  *ITGB3*    34×                1a+, 1b+, 4a+, 4b−, 6bw−, 7bw−, 8bw−, 10bw−, 11bw−, 14bw−, 16bw−, 17bw−, 19w−, 21w−, 23bw−, 26bw−
  *GP1BA*    25×                2a+, 2b−
  *ITGA2B*   27×                3a+, 3b−, 9bw−, 20w−, 22bw−, 24bw−, 27bw−, 28bw−
  *ITGA2*    40×                5a+, 5b−, 13bw−, 18w−, 25bw−
  *GP1BB*    21×                12bw−
  *CD109*    39×                15a−, 15b+

Variant calling on WGS data determined the nucleotide positions that differed in relation to the human reference genome. The sequence alignments between the human reference genome CDS and the cDNA reference sequence were then used as a guide to convert genomic coordinates from the variant calling process into the conventional CDS positions. By combining the human reference genome antigen predictions with manual identification of the CDS converted variants using published allele tables,[2](#trf13416-bib-0002){ref-type="ref"}, [3](#trf13416-bib-0003){ref-type="ref"}, [4](#trf13416-bib-0004){ref-type="ref"}, [10](#trf13416-bib-0010){ref-type="ref"}, [12](#trf13416-bib-0012){ref-type="ref"}, [23](#trf13416-bib-0023){ref-type="ref"} the WGS data were used to comprehensively predict all RBC and PLT antigens (Tables [3](#trf13416-tbl-0003){ref-type="table-wrap"} and [4](#trf13416-tbl-0004){ref-type="table-wrap"}). As part of the process, nucleotide changes were found that are not known to encode antigenic epitopes; while most were silent changes that did not alter the amino acid sequence, there were a few missense changes that do alter the amino acid sequence (Table [5](#trf13416-tbl-0005){ref-type="table-wrap"}). A RBC sample was tested for RBC antigens using available commercial serologic typing reagents and all of the antigen predictions were correct for the serologically tested RBC antigens (ABO, D, c, C, e, E, K, k, Fy^a^, Fy^b^, Jk^a^, Jk^b^, M, N, S, and s).

###### 

Changes not known to encode new or altered antigenic epitopes

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gene       CDS nucleotide (genomic coordinate) and \[amino acid\]
  ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  *GYPA*     hom c.38(chr4:145,041,741)A\>C \[missense p.Glu13Ala\]\
             Note: aa position 13 is within the N‐term of protein which is cleaved from the native protein.

  *A4GALT*   het c.109(chr22:43,089,849)A\>G \[missense p.Met37Val\]

  *CR1*      het c.3623(chr1:207,753,621)A\>G \[missense p.His1208Arg\]; het c.5480(chr1:207,790,088)C\>G \[missense p.Pro1827Arg\]; hom c.5905(chr1:207,795,320)A\>G \[missense p.Thr1969Ala\]

  *CD109*    hom c.3722(chr6:74,521,947)C\>T \[missense p.Thr1241Met\]
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

hom = homozygous, het = heterozygous

DISCUSSION {#trf13416-sec-0025}
==========

Advantages of antigen prediction by WGS {#trf13416-sec-0026}
---------------------------------------

In this analysis we showed that it is possible to perform comprehensive RBC and PLT antigen prediction using WGS data. WGS‐based antigen prediction has advantages over current methods such as DNA CHIP, polymerase chain reaction, and Sanger sequencing. Although the current commercial DNA chip‐based assays enable antigen prediction, they are limited in the number of SNPs analyzed, which impacts unambiguous allele resolution. Assays for the RH blood group system are not capable of detecting all known variant RH alleles and additional assays need to be performed to determine *RHD* zygosity. Sanger sequencing could be used to determine all of the known alleles, but the method is labor‐intensive and requires the development and validation of many individual assays. In contrast, NGS‐based sequencing can evaluate whole gene sequences and detect gene rearrangements, and copy number analysis could determine zygosity. Laboratories could use whole genome or exome approaches or develop targeted NGS‐based panels that allow for more affordable sequencing of specific genomic regions by pooling patient specimens using molecular barcodes. In addition, the current generation of benchtop NGS instruments have a 24‐ to 48‐hour turnaround time.

Considerations for antigen prediction with WGS {#trf13416-sec-0027}
----------------------------------------------

Traditional serologic antigen testing for the most commonly tested antigens (ABO, D, c, C, e, E, K, k, Fy^a^, Fy^b^, Jk^a^, Jk^b^, M, N, S, and s), performed independently and without knowledge of the WGS predictions, agreed with the WGS‐based antigen predictions. Although the prediction algorithms successfully predicted the ABO, C/c, M/N, and S/s antigens in this first genome analysis, it is anticipated that these antigens might be more challenging to reliably predict in patients with more extensive genomic variation. In general, robust and reliable automated algorithms for predicting ABO and other carbohydrate antigens require the integration of analyses across several genes. Furthermore, the known alleles for the carbohydrate antigens and the duplicated gene families *GYPA*/*GYPB* and *RHD*/*RHCE* often rely on multiple distant variant positions and haplotype ambiguities can occur due to the short read length of most current WGS platforms. Resolution of these ambiguities will ultimately require sequencing technologies that allow for longer read lengths, but in the meantime allele population prevalence could be used to select the most likely haplotype.

The correct alignment of NGS sequence reads is anticipated to be more difficult in the duplicated gene families *GYPA*/*GYPB* and *RHD*/*RHCE*. For example, the C antigen results from gene transfer of Exon 2 from *RHD* into *RHCE*, thus the NGS reads for a C+ *RHCE* Exon 2 might misalign to *RHD* Exon 2 without the appropriate algorithm. Similar issues with alignment are likely to occur with other gene rearrangements. However, it might be possible to use the sequence read depth along each gene to look for misaligned sequences to infer the correct antigen or find a rearrangement. NGS rearrangement detection algorithms[61](#trf13416-bib-0061){ref-type="ref"} could also be used to look for the rearrangement breakpoint. Prediction algorithms capable of detecting *RHD*/*RHCE* rearrangements would be of great value in detecting these potential clinically significant changes in sickle cell patients and pregnant women with weak D or partial D phenotypes. Performing NGS‐based RBC predictions on a diverse population of serologically and conventionally molecularly typed individuals will aid development of interpretation algorithms.

Clinical benefits of antigen prediction with WGS {#trf13416-sec-0028}
------------------------------------------------

Oncology patients often receive RBC and PLT transfusions. For a minor added cost RBC and PLT antigen prediction could be added to NGS assays already being performed for oncologic diagnosis and drug selection. It might also be possible to replace the current SNP‐based antigen typing assays with targeted NGS‐based RBC and PLT predictions to aid in difficult serologic work‐ups and PLT refractory evaluations and help prevent alloantibody formation in chronically transfused patients. As clinical WGS becomes more commonplace for general disease screening and risk assessment, these existing WGS data could be used for large population level antigen prediction. This would allow for easy identification of donors; assist with compatibility testing of alloimmunized recipients; and prevent alloantibody formation using extended prophylactic matching and the identification of individuals at increased risk for posttransfusion purpura, hemolytic disease of the newborn or fetus, and neonatal alloimmune thrombocytopenia.

Future directions {#trf13416-sec-0029}
-----------------

In this article, we have shown proof of principle that it is possible to comprehensively predict RBC and PLT antigens from WGS data. WGS‐based antigen predictions may someday enable accurate determination of blood group antigens, including ABO and RH, at a level of fidelity that cannot be achieved with current DNA chip analysis. To fully realize this potential, we are currently developing and validating prediction algorithms capable of automatically detecting and integrating across the known antigen alleles, which will allow for quick and easy antigen prediction from both WGS and targeted NGS. We are also extending our analysis algorithms for use with the newest human reference genome (GRCh38).
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**Fig. S1.** WGS antigen gene coverage.

###### 

Click here for additional data file.
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